Document:

QuickLinks
 -- Click here to rapidly navigate through this document

Exhibit 10.12  

 
  EXCLUSIVE LICENSE AGREEMENT
  AMONG
  GEORGETOWN UNIVERSITY
  AND
  THE UNIVERSITY OF ARIZONA
  AND
  PROLX PHARMACEUTICALS CORPORATION    
    

        Effective as of 5th day of July, 2001, GEORGETOWN UNIVERSITY ("GEORGETOWN"), a not-for-profit academic institution organized
under the laws of the District of Columbia, having a principal address at 37th & O Streets, N.W., Washington, D. C. 20057, and The Arizona Board of Regents on behalf of THE
UNIVERSITY OF ARIZONA ("ARIZONA"), with its principal offices in Tucson, Arizona 85721 (hereinafter collectively referred to as "LICENSOR"), and PROLX PHARMACEUTICALS CORPORATION, having a principal
place of business at 1401 Forbes Avenue, Suite 231, Pittsburgh, Pennsylvania, 15219-5125 ("LICENSEE"), agree as follows: 

1. BACKGROUND  

         1.1  GEORGETOWN
and ARIZONA through collaboration invented and discovered certain Technology as further defined herein. 

         1.2  GEORGETOWN
and ARIZONA are the owners by assignment or obligation of assignment to said Technology as further defined herein. 

         1.3  GEORGETOWN
and ARIZONA wish to have the Technology developed and marketed at the earliest possible time in order that products resulting therefrom may be available for
public use and benefit. As a result, GEORGETOWN and ARIZONA have entered into an Interinstitutional Agreement (the "Interinstitutional Agreement") that sets forth the rights and obligations of each to
the other. 

         1.4  LICENSEE
wishes to acquire an Exclusive license from LICENSOR under said Technology for the purpose of undertaking development, to manufacture, use, import and sell
products incorporating said Technology. 

2. DEFINITIONS  

         2.1  "Exclusive" means LICENSOR has not granted and shall not grant further licenses under the Technology so long as this
Agreement is in effect, and shall not make, have made, use, sell, or offer to sell Licensed Products. 

         2.2  "Field of Use" means any and all fields of use, including the fields of drug design, drug discovery, pharmaceuticals,
therapeutics, and diagnostics. 

         2.3  "First Commercial Sale" means the first sale of a Licensed Product at an arms length transaction with a third party
unaffiliated with any party to this Agreement. 

         2.4  "Licensed Application(s)" means the applications identified in Appendix A, and all U.S. or foreign patent
applications and equivalents thereto claiming Technology, and all divisionals, continuations, reissues, and reexaminations thereof, and continuations-in-part, and applications
claiming priority therefrom. 

         2.5  "Licensed Patent(s)" means the patents identified in Appendix A and any U.S. or foreign patents issued or granted
from the Licensed Applications and any and all existing or future foreign counterparts of the patents listed in Appendix A or of patents issued or granted from the Licensed Applications, along
with any continuations, divisions, continuations-in-part, confirmations, substitutions, registrations, revalidations, additions, extensions, re-examination
certificates, supplementary protection certificates and reissues thereof. 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

 

         2.6  "Licensed Product(s)" means any compound, product or part thereof, device, kit, method or service, the manufacture, use,
import or sale of which is covered by a valid claim of an issued, unexpired Licensed Patent(s). A claim of an issued, unexpired Licensed Patent(s) shall be presumed to be valid unless and until it has
been held to be invalid by a final judgment of a court of competent jurisdiction from which no appeal can be or is taken. 

         2.7  "LICENSEE" is understood to include ProlX Pharmaceuticals Corporation and any and all of its Affiliates. An Affiliate of
LICENSEE shall mean any corporation or other business entity controlled by, controlling, or under common control with LICENSEE during the term of this Agreement. For this purpose, "control" means
direct or indirect beneficial ownership: 

	(a)
	of
at least fifty percent (50%) of the voting stock; or

	(b)
	of
at least fifty percent (50%) interest in the income of such corporation or other business. 

         2.8  "Net Sales" means the gross revenue generated by sale or use of the Licensed Product(s) in the form in which it is sold
or used, less the following items: 

	(a)
	Import,
export, excise, value added and sales taxes, plus custom duties;

	(b)
	Costs
of insurance, packing and transportation from the place of manufacture to the customer's premises or point of installation;

	(c)
	Normal
and customary quantity and cash discounts; and

	(d)
	Credit
for returns, allowances, or trades actually given. 

        For
Licensed Products sold or otherwise provided in combination with other products or services, or provided in other than a sale transaction, Net Sales shall be based on the quantity of
products or services provided times the price for a similar product or service when sold or otherwise provided separately by LICENSEE in an arms-length transaction in similar quantities. 

         2.9  "Regulatory Approval" means any approval or clearance by any governmental agency or agencies having authority to regulate
the use or sale of any Licensed Product(s) in the pertinent jurisdiction or territory. 

       2.10  "Technology" means the Licensed Application(s) and Licensed Patents as well as any technical data, know-how,
material, research results and other information provided to LICENSEE by LICENSOR or its employees or contractors including, without limitation, any biochemical, preclinical, clinical, manufacturing,
formulation, and scientific research information of a confidential nature whether patentable or unpatentable, relating to, but limited to the subject matter described or claimed in, the Licensed
Application(s) and/or Licensed Patent(s) as listed in APPENDIX A. 

3. GRANT  

         3.1  LICENSOR
hereby grants and LICENSEE hereby accepts an exclusive, even as to LICENSOR, worldwide license to make, have made, use, sell, have sold, offer for sale, import,
and otherwise obtain or provide Licensed Product(s) and to use Technology in the Field of Use. Notwithstanding the preceding sentence, LICENSORS shall retain the right to use the Technology for
internal educational and research purposes within each LICENSOR's respective institution. 

         3.2  Said
license is transferable and includes the right to sublicense. The terms and conditions of any transfer or sublicense shall be consistent with the terms and
conditions of this Agreement and LICENSOR shall have the right to approve such transfer or sublicense, which approval shall not be withheld absent a clear potential to adversely affect the financial
consideration anticipated under the 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

2

 

license.
The approval of LICENSOR shall also be required in connection with any transfer or sublicense to any Affiliate of LICENSEE, which approval shall not be unreasonably withheld. 

4. ROYALTIES, PAYMENTS AND MILESTONES  

         4.1  LICENSEE
agrees to reimburse GEORGETOWN a total of [+] for costs incurred to date in connection with the preparation, filing and prosecution of
the Licensed Applications. After the effective date, and during the term of this Agreement, LICENSEE agrees to assume responsibility for future patent prosecution and maintenance costs as provided in
the following Article 7.1. 

         4.2  LICENSEE
shall pay to LICENSOR benchmark royalties relating to each Licensed Product as follows: 

	(1)
	[+]

	(2)
	[+]

	(3)
	[+];
and

	(4)
	[+].

        LICENSEE
may investigate more than one Licensed Product through Phase II tests, without paying more than one set of benchmark royalties. If LICENSEE should choose to submit multiple NDAs
or an NDA covering more than one Licensed Product, then the benchmark royalties relating to additional Licensed Products as set forth in 4.2 (3) and (4) above shall be reduced by
[+]. If, after obtaining approval of an NDA, LICENSEE attempts to develop additional Licensed Products, benchmark royalties relating to such products will be reduced by
[+]. 

         4.3  In
addition, LICENSEE shall pay LICENSOR earned royalties on Net Sales of Licensed Product sold directly by LICENSEE in the country in which the Licensed Product is
made, used or sold. The royalty shall be [+] for all Fields of Use. If the Licensed Product is sublicensed, LICENSEE shall pay to LICENSOR a sublicensing fee as a percentage of
revenues received by LICENSEE. For pharmaceuticals and therapeutics, LICENSOR's share of sublicense revenues shall be [+] until [+] and
[+] thereafter. For diagnostics, LICENSOR's share of sublicense revenues shall be [+] until [+], and [+]
thereafter. 

         4.4  The
royalty on sales in currencies other than U.S. Dollars shall be calculated using the appropriate foreign exchange rate for such currency quoted by the Wall Street
Journal, on the close of business on the last banking day of each calendar quarter. Royalty payments to LICENSOR shall be in U.S. Dollars. 

5. REPORTS, PAYMENTS AND ACCOUNTING  

        5.1    Quarterly Royalty Payment and Report.    LICENSEE shall make written reports and royalty payments to ARIZONA
within [+] days after the end of each calendar quarter following the First Commercial Sale. This report shall state the number, description, and aggregate Net Sales of
Licensed Product(s) during such completed calendar quarter, and resulting calculation of earned royalty payment due the LICENSORS for such completed calendar quarter. Concurrent with the making of
each such report, LICENSEE shall include payment due LICENSORS of royalties for the calendar quarter covered by such report. 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

3

 

        All
Payments pursuant to the License shall be made and sent to the following address: 

	Frank Hartdegen, Ph.D., Director	 	 
	Office of Technology Transfer

The University of Arizona

P. O. Box 210151

Tucson, AZ 85721-0151	 	if express mail:

Babcock Bldg., Rm. 3205

1717 Speedway Blvd.

Tucson, AZ 85721-0151

        5.2    Annual Progress Reports.    LICENSEE shall provide to ARIZONA annual written progress reports with the first
Quarterly Report for each calendar year after the effective date of this agreement. The reports shall include sufficient detail to allow LICENSOR to determine progress on research and development,
manufacturing, sublicensing, marketing and sales during the previous twelve (12) months as well as plans for the coming year. 

        5.3    Accounting.    LICENSEE agrees to keep records for a period of two (2) years showing the manufacturing,
sales, use, and other disposition of products sold or otherwise disposed of under the license herein granted in sufficient detail to enable the royalties payable hereunder by LICENSEE to be
determined, and further agrees to permit its books and records to be examined from time to time by a certified public accountant of a nationally recognized accounting firm, who is selected and paid
for by ARIZONA, but no more than once per calendar year to the extent necessary to verify reports provided for in Paragraph 5.1 and no later than two years after a particular Quarterly Report
is made. Such examination is to be made by ARIZONA, at its expense and all such information obtained shall be treated as confidential information pursuant to Article 9. If ARIZONA determines
that LICENSEE
has, for any reason, failed to pay adequate royalties, LICENSEE shall immediately upon notice thereof pay to ARIZONA any owed royalties plus interest at the rate of [+] per
annum, compounded daily, calculated from the date upon which such royalties should have been paid to the date of actual payment of ARIZONA. 

6. REPRESENTATIONS  

         6.1  Each
LICENSOR represents and affirms that it has the right to grant LICENSEE the license granted herein and that it has not granted any license to the Licensed Patents
or Licensed Applications or any rights in any Licensed Product(s) to any third party, except for United States government rights which may have been required by law. 

         6.2  Each
LICENSOR represents and affirms that, to such LICENSOR's knowledge, information and belief: 

	(a)
	there
are no patents, applications, or invention disclosures owned or assigned to a LICENSOR relating to the Technology other than those listed on Appendix A;

	(b)
	there
is no material prior art of which LICENSOR and its employees and contractors are aware that has not been provided to patent counsel; and

	(c)
	other
than the Licensors, there are no co-owners of the Licensed Applications and Licensed Patents, except as set forth herein. 

         6.3  Each
LICENSOR represents to LICENSEE that such LICENSOR shall be liable for all claims, damages, or suits arising from the acts, omissions, or negligence of its
respective officers, agents, and employees. 

         6.4  EXCEPT
AS OTHERWISE EXPRESSLY SET FORTH IN THIS AGREEMENT, LICENSOR MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING,
BUT NOT LIMITED TO, WARRANTY 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

4

 

OF
MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND VALIDITY OF PATENTED RIGHTS CLAIMS, ISSUED OR PENDING. 

         6.5  EXCEPT
FOR ITS OBLIGATIONS OF COOPERATION AS SET FORTH IN SECTION 8 HEREOF, NOTHING IN THIS AGREEMENT, EITHER EXPRESS OR IMPLIED, OBLIGATES LICENSOR EITHER TO BRING OR
TO PROSECUTE ACTIONS OR SUITS AGAINST THIRD PARTIES FOR PATENT INFRINGEMENT OR TO FURNISH ANY KNOW-HOW OR TRADE SECRETS NOT PROVIDED IN LICENSOR'S LICENSED PATENTS OR LICENSED
APPLICATIONS. 

         6.6  IN
NO EVENT SHALL LICENSOR BE LIABLE FOR ANY INCIDENTAL, SPECIAL, OR CONSEQUENTIAL DAMAGES RESULTING FROM THE EXERCISE OF THIS LICENSE OR THE USE OF THE LICENSED
TECHNOLOGY OR LICENSED PRODUCTS. 

         6.7  NO
WARRANTY OR REPRESENTATION IS MADE THAT ANYTHING MADE, USED, OR SOLD UNDER THE TERMS OF THIS AGREEMENT WILL BE FREE FROM INFRINGEMENT OF ANY THIRD PARTY PATENTS. 

         6.8  THIS
AGREEMENT DOES NOT CONFER BY IMPLICATION, ESTOPPEL, OR OTHERWISE ANY LICENSE OR RIGHTS TO ANY OTHER PATENT OF LICENSOR OTHER THAN PATENT RIGHTS AS EXPRESSLY STATED
HEREIN, REGARDLESS OF WHETHER SUCH PATENTS ARE DOMINANT OR SUBORDINATE TO PATENT RIGHTS. 

7. PROSECUTION OF LICENSED PATENTS  

         7.1  LICENSEE
agrees to accept liaison and financial responsibilities, as hereinafter set forth, for the prosecution, by a patent lawyer in independent practice, who shall be
nominated by LICENSEE and approved by LICENSOR, of the Licensed Applications listed on Appendix A, and additional applications as the parties may subsequently agree. Said financial
responsibilities shall not only include the costs of prosecution but also the payment of maintenance fees, where required, to maintain said patent applications and patents, if issued, in force and
effect for as long as possible. It is further agreed that the patent lawyer selected and paid by LICENSEE and approved by LICENSOR shall be required, if so desired by LICENSOR, to keep a patent lawyer
selected by LICENSOR informed of all steps in the prosecution and maintenance of said Patent Rights. Notice of prosecution and maintenance of said Patent Rights shall be sent to: 

	Kelli N. Watson, Esq.

Research & Technology Development Services

Georgetown University Medical Center

Suite 177, Building D

4000 Reservoir Road, N.W.

Washington, D.C. 20007	 	 
	

And	
 	

 
	

Frank Hartdegen, Ph.D., Director	
 	

 
	Office of Technology Transfer

The University of Arizona

P. O. Box 210151

Tucson, AZ 85721-0151	 	if express mail:

Babcock Bldg., Rm. 3205

1717 Speedway Blvd.

Tucson, AZ 85721-0151

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

5

 

If,
for any reason, prosecution or maintenance of a particular patent application or patent in a particular country is to be abandoned by LICENSEE, LICENSOR will be notified in sufficient time to
assume prosecution. LICENSEE shall bear all cost to maintain the patent prosecution until such time that LICENSOR can assume patent prosecution. 

         7.2  Within
two (2) weeks of notification to LICENSOR by LICENSEE of the identity of the patent lawyer, LICENSOR or its current counsel will furnish complete file
histories of all of the patent applications constituting said Licensed Applications to the patent lawyer nominated in accordance with Paragraph 7.1 above. 

         7.3  Each
LICENSOR shall have the right at any time, by notice in writing and sent to LICENSEE by registered mail, to assume and continue at its own expense, direction of the
prosecution of any of said Licensed Applications. Upon receipt by LICENSEE of any such notice from a LICENSOR, and upon consent of the other LICENSOR, LICENSEE and the patent lawyer nominated in
accordance herewith shall provide in two weeks from the time of notice an executed power of attorney and all the file histories of the patent applications constituting said Licensed Applications. Upon
receipt of this documentation, LICENSEE and the patent attorney nominated by LICENSEE shall be relieved of all future responsibilities to prosecute the Licensed Applications to which the notice is
directed. In which event, LICENSOR agrees to use its good faith efforts to apply for, seek prompt issuance of, and maintain during the term of this Agreement, Patent Rights to the extent necessary to
cover both broadly and specifically Licensed Products. LICENSEE shall have reasonable opportunity to advise LICENSOR and shall cooperate with LICENSOR in such filing, prosecution and maintenance.
LICENSOR shall use its good faith efforts to furnish LICENSEE with copies of any patent application sufficiently in advance of its anticipated filing date to give LICENSEE a reasonable opportunity to
review and comment thereon. In this event, LICENSOR also agrees to furnish LICENSEE with copies of all substantive communications to and from U.S. and foreign patent offices regarding Licensed
Applications and in good faith shall consider the reasonable comments of LICENSEE regarding all communications and filings to and from the respective patent office. 

8. INFRINGEMENT  

         8.1  LICENSOR
and LICENSEE shall promptly give notice to the other in writing of any alleged infringement of Patent Rights. The parties shall thereupon confer as to what
steps are to be taken to stop or prevent such infringement. 

         8.2  LICENSEE
shall have the first right to defend Patent Rights against any infringer at LICENSEE's cost and expense including by bringing any legal action for infringement
or defending any counterclaim of invalidity or action of a third party for declaratory judgment of non-infringement, which LICENSEE, in its sole discretion, decides is reasonable and
necessary for it to undertake. LICENSEE shall bring or defend or may settle any such actions solely at its own expense and through counsel of its selection and will be entitled to retain any
settlement or damage award received except as provided for in Article 8.5; provided, however, that each LICENSOR shall be entitled in each instance to participate through counsel of its own
selection and its own expense. LICENSEE and each LICENSOR acknowledge and agree that, although each LICENSOR shall have the right at such LICENSOR's option to prosecute infringers as provided in the
following Article 8.3, LICENSOR is not desirous of being a party to any such infringement suit. LICENSEE shall not join LICENSOR as a party-plaintiff in any suit which LICENSEE may institute
unless necessary for the maintenance of said suit, and then only with the prior knowledge and written consent of LICENSOR, which consent shall not be unreasonably withheld. In such event, LICENSOR
shall not be chargeable for any costs or expenses. LICENSOR shall execute all documents necessary for the prosecution of any infringement suit brought by LICENSEE and provide other such support as
LICENSEE may require including having its employees testify when requested and make available relevant records, papers, information, samples, specimens and the like, all however at the expense, with
respect to travel and the like, of LICENSEE. 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

6

 

         8.3  LICENSOR
shall have the right to defend the Patent Rights against infringement in the event that LICENSEE declines to exercise its rights to defend Patent Rights under
Article 8.2 and shall have sole discretion to file and prosecute, defend or settle such infringement and declaratory judgment action at its own expense through counsel of its own selection and
will be entitled to retain any settlement or damage award received; provided, however, that LICENSEE shall be entitled in each instance to participate through counsel of its own selection and at its
own expense. LICENSEE shall have no responsibility or financial obligation with respect to any such infringement action except to provide reasonable assistance to LICENSOR as requested and LICENSOR
shall reimburse LICENSEE for LICENSEE's out-of-pocket expenses in connection with any such assistance. LICENSEE shall execute all documents necessary for the prosecution of any
infringement suit brought by LICENSOR and provide other such support as LICENSOR may require, including having its employees testify when requested and make available relevant records, papers,
information, samples, specimens and the like, all however at the expense, with respect to travel and the like, of LICENSOR. 

         8.4  In
the event that LICENSOR decides to institute suit, LICENSOR shall be entitled to retain the entire amount of any recovery or settlement, less all reasonable costs,
including attorneys fees, incurred by LICENSEE as a consequence. Furthermore, at its option, LICENSOR may join LICENSEE as plaintiff. 

         8.5  LICENSOR
shall be entitled to the percentage of any recovery obtained in any infringement suit brought by LICENSEE equal to the amount to which LICENSOR would be
entitled under the sublicensee royalty provision of this Agreement had said recovery been paid to LICENSEE as sublicense royalties by the defendant in said infringement suit. LICENSEE may deduct its
reasonable costs and attorneys' fees incurred in prosecuting such suit, to the extent such costs and fees are not otherwise recovered, prior to calculating the share owing to LICENSOR pursuant to this
provision. 

         8.6  Should
either LICENSOR or LICENSEE commence a suit under the provisions of Paragraphs 8.2 or 8.3 and thereafter elect to abandon the same, it shall give timely notice to
the other party which may, if it so desires, continue prosecution of such suit; provided, however, that the sharing of expenses and any recovery in such suit shall be agreed upon between LICENSOR and
LICENSEE. 

         8.7  LICENSEE
during the period of this Agreement, shall have the sole right in accordance with the terms and conditions herein to sublicense any alleged infringer, and
LICENSOR shall be entitled to royalties therefrom as specified in Paragraph 4.3. 

9. PUBLICITY AND CONFIDENTIALITY  

         9.1  Neither
party shall use the name of the other in any form of advertising or promotion without the prior written approval of the other, except to announce this Agreement. 

         9.2  Confidential Items.    Confidential Items shall mean any proprietary information or materials belonging to the
disclosing party clearly marked CONFIDENTIAL (whether or not patentable) including, but not limited to, patent filings, formulations, techniques, methodology, equipment, data, reports,
know-how, sources of supply, patent positioning, consultants and business plans, including any negative developments, which are communicated to, learned by, or otherwise acquired by the
party receiving such information or materials during or in the course of this Agreement, further including information concerning the existence, scope or activities of any research and development
project of the disclosing party. 

         9.3  Each
party shall hold in confidence for a period of five (5) years, and shall not disclose to any person outside its respective organization, any Confidential
Items disclosed to it by the other party to this Agreement. The party receiving such Confidential Items shall use such Confidential Items only for the limited purpose for which it was disclosed and
shall not exploit such Confidential Items for its own benefit or the benefit of another without the prior written consent of the disclosing party. Each party shall disclose Confidential Items of the
other party under this Agreement only to persons within its organization and to consultants who have a need to know such Confidential Items in the course of the 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

7

 

performance
of their duties and who are bound to protect the confidentiality of such Confidential Items. 

         9.4  The
confidentiality and non-use obligations of the receiving party shall not apply to any Confidential Item(s) which is received by one party from the other
party and which: 

	(i)
	is
disclosed in a printed publication available to the public, is described in an issued patent anywhere in the world, is otherwise in the public domain at the time of
disclosure, or becomes publicly known through no breach of this Agreement by the receiving party;

	(ii)
	becomes
known to the receiving party through disclosure by sources other than the disclosing party having the right to disclose such Confidential Items;

	(iii)
	is
disclosed pursuant to the requirements of a governmental agency or any law requiring disclosure thereof, provided that the disclosing party is provided with prior
written notice of any such disclosure;

	(iv)
	is
generally disclosed to third parties by the disclosing party without similar restrictions on such third parties;

	(v)
	is
approved for release by written authorization of an officer of the disclosing party;

	(vi)
	is
already known by the receiving party as evidenced by its prior written records; or

	(vii)
	is
developed by receiving party independently of and without reference to Confidential Items received from disclosing party as evidenced by written record. 

provided,
however, that a breach of the foregoing obligations shall not be absolved by the subsequent occurrence of any of the above exceptions. 

10. PUBLICATION  

       10.1  Subject
to all other terms of this Agreement, including those concerning confidentiality, LICENSORS' investigators have the right to publish or otherwise publicly
disclose information. However, LICENSOR will provide LICENSEE with copies of articles reporting on research involving the Technology as soon as practicable but in no event later than simultaneously
with their submission for publication to a peer-reviewed publication and will timely provide an outline of any other public disclosure in order to provide LICENSEE an opportunity to
determine if patentable inventions or Confidential Items will be disclosed. 

11. DUE DILIGENCE  

       11.1  LICENSEE
shall use good faith efforts to develop, obtain clinical approval for, manufacture, market and promote Licensed Products. 

       11.2  LICENSEE
shall use good faith efforts to: 

	(a)
	market
Licensed Products for sale within [+] of receiving regulatory approval by the appropriate governmental agency in each country in the world, including
the U.S. Food and Drug Administration; and

	(b)
	develop
and construct manufacturing facilities suitable for producing commercial quantities of Licensed Products. 

       11.3  After
an initial period of [+] from the effective date of this Agreement, LICENSOR may exclude a Field of Use or a portion thereof from the
license granted herein pursuant to the provisions set forth in this section 11.3. In the event both LICENSORS agree that LICENSEE is not making reasonable efforts to commercialize a Field of
Use of the Licensed Applications) and/or 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

8

 

Licensed
Patent(s), the LICENSORS shall, by written notice to LICENSEE, signed by both LICENSORS, particularly identify that Field of Use. After such time notice is given, LICENSEE shall have a
[+] period to file for Investigatory New Drug ("IND") approval if required for the identified Field of Use and/or to pursue commercialization of identified Field of Use. In the
event LICENSEE elects not to pursue IND approval as provided in writing to LICENSOR, the identified Field of Use or portion thereof shall be excluded from the license granted to LICENSEE, (hereinafter
referred to as "Excluded Field of Use"). Thereafter, the LICENSOR shall have the right to grant licenses to third parties for the Excluded Field of Use, subject to LICENSEE's right to match the third
party offer to license the Excluded Field of Use within [+] written notice of the third party offer. 

12. TERM AND TERMINATION  

       12.1  Term of License. 

	(a)
	The
Term of this Agreement shall be for a period beginning with the Effective Date and extending until the last to expire valid claim of a Licensed Patent covering a Licensed Product,
unless sooner terminated as herein provided. Surviving any termination are: (a) LICENSEE's obligation to pay royalties accrued or accruable for sell-off of inventory pursuant to
Paragraph 12.1(d); and (b) any cause of action or claim of LICENSEE or LICENSOR, accrued or to accrue, because of any breach or default by the other party.

	(b)
	Subject
to the provisions of Section 11.3 hereof, which describes the only method by which LICENSOR shall be entitled to terminate this Agreement on the basis of failure to use
appropriate diligence, upon any material breach or default under this Agreement by LICENSEE, LICENSOR may give written notice thereof to LICENSEE, and LICENSEE shall have sixty (60) days
thereafter to cure such breach or default. If such breach or default is not so cured, LICENSOR may then in its sole discretion and option (a) terminate this Agreement and the licenses granted
herein or (b) seek such other relief as may be provided by law in such circumstances by giving written notice thereof to LICENSEE.

	(c)
	LICENSEE
shall have the right to terminate this Agreement at any time upon ninety (90) days written notice to LICENSOR and payment of all amounts due LICENSOR through the
effective date of termination.

	(d)
	Upon
termination of this Agreement under any provision, all further obligations of the parties under this Agreement shall terminate without further liability of any party to another;
provided, however, that the publicity and confidentiality obligations of the parties contained in Article 9 hereof, shall survive any such termination for the periods set forth therein.
Termination shall not relieve any party of any obligation occurring prior to such termination, of any liability for a breach of, or for any misrepresentation under this Agreement or be deemed to
constitute a waiver of any available remedy (including specific performance if available) for any such breach or misrepresentation, provided, however, that neither party shall be liable for
consequential, punitive or special damages including without limitation, lost profits. LICENSEE and any sublicensee thereof may, however, after the effective date of such termination, sell all
Licensed Products, and complete Licensed Products in the process of manufacture and fulfill all orders for Licensed Products at the time of such termination and sell the same, provided that LICENSEE
shall pay to LICENSOR the royalties thereon as required by Article 4 of this Agreement and shall submit the reports required by Article 5 hereof on the sales of such Licensed Products. 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

9

 

	(e)
	In
the event of termination of this Agreement for any reason, any and all rights granted LICENSEE hereunder, including any rights granted by LICENSEE to any sublicensee, shall cease
and terminate, and all such rights shall revert to LICENSOR. LICENSEE shall diligently thereafter return to LICENSOR, or to LICENSOR's designated attorneys, any files or other documents in its
possession or in the possession of its attorneys, agents or sublicensees, relating to pending or issued Licensed Patent(s), except that one copy of each such document may be retained by LICENSEE's
attorney for the purpose of ensuring compliance hereunder. LICENSEE shall also execute any and all documents necessary to return control of said Licensed Patent(s) until such time as control has
properly been transferred to LICENSOR. Further, LICENSEE shall immediately return to LICENSOR all research data, biological and other material (including but not limited to licensed cell lines),
prototypes, process information, clinical data and the like of LICENSOR in its possession or in the possession of its sublicensees. 

13. ASSIGNMENT  

       13.1  This
Agreement shall not be assignable by either party without the prior written consent of the other party, such consent not to be unreasonably withheld.
Notwithstanding however, LICENSEE may assign this Agreement to an entity, which acquires all or substantially all of the assets to which this Agreement pertains without the prior written consent of
LICENSOR. 

14. INDEMNIFICATION  

       14.1  LICENSEE
agrees that during the term of this Agreement and thereafter, it will indemnify, defend and hold LICENSOR, its trustees, officers, employees and affiliates,
harmless against all claims and expenses, including legal expenses and attorneys' fees, arising out of the death of or injury to any person or persons, or out of any damage to property, and against
any other claim, proceeding, demand, expense and liability of any kind whatsoever resulting from the production, manufacture, sales, use, consumption, disposal or advertisement of Licensed Products by
LICENSEE. 

15. NOTICES  

       15.1  All
notices under this Agreement shall be deemed to have been fully given when done in writing and deposited in the United States mail, registered, certified or
express, and addressed, or when actually received, as follows: 

	TO LICENSOR:	 	Frank Hartdegen, Ph.D., Director	 	 
	 	 	Office of Technology Transfer

The University of Arizona

P. O. Box 210151

Tucson, AZ 85721-0151	 	if express mail:

Babcock Bldg., Rm. 3205

1717 Speedway Blvd.

Tucson, AZ 85721-0151
	

TO LICENSEE:	
 	

Dr. Lynn Kirkpatrick

ProlX Pharmaceuticals Corporation

1401 Forbes Avenue, Suite 231

Pittsburgh, Pennsylvania 15219-5125	
 	

 

Either
party may change its address upon notice to the other party as provided herein. 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

10

 
16. DISPUTE RESOLUTION  

       16.1  Should
the parties hereafter have any dispute as to their obligations pursuant to this Agreement, they shall first attempt to resolve such dispute among themselves. If
such efforts are not successful, the parties shall select a neutral party to mediate the dispute. 

       16.2  Either
party may elect to submit the issue to arbitration by giving written notice to the other party and naming an arbitrator. The other party will then have thirty
(30) days to select its own arbitrator. Once both arbitrators have been selected they shall meet within thirty (30) days of the appointment of the second arbitrator and select a third
arbitrator mutually agreeable to them. 

       16.3  Once
the panel of arbitrators has been chosen, they shall conduct arbitration on the disputed issue or issues in accordance with the Commercial Arbitration Rules of the
American Arbitration Association. The third arbitrator shall serve as the presiding arbitrator, although, in the event of dispute among the arbitrators, the majority decision of the arbitration panel
shall be binding. The decision of the arbitrators shall be final and either party may apply to a court of competent jurisdiction to enter judgment based on the arbitrator's decision. All costs of the
arbitrators and arbitration, other than the respective parties' attorneys' fees and costs, shall be borne equally by the parties. 

17. GENERAL PROVISIONS  

        17.1    Equal Opportunity.    The parties agree to be bound by applicable state and federal rules governing equal
employment opportunity and nondiscrimination. 

        17.2    State Funding.    All parties recognize that ARIZONA's performance may be dependent upon the appropriation of
funds by its state legislature. Should the Legislature of Arizona fail to appropriate the necessary funds, ARIZONA may cancel this Agreement without further duty or obligation. ARIZONA agrees to
notify the other parties as soon as reasonably possible after the unavailability of said funds comes to ARIZONA's attention. 

        17.3    Conflict of Interest.    This Agreement is subject to the provisions of A.R.S. §
38-511 and conflict of interest laws of the State of Arizona. ARIZONA may cancel this
Agreement by written notice to the other parties if any person employed by the State of Arizona is substantially involved in obtaining, drafting, or procuring this Agreement for or on behalf of the
parties becomes an employee or consultant in any capacity of the LICENSEE. 

        17.4    Waiver.    None of the terms, covenants and conditions of this Agreement can be waived except by the written
consent of the party waiving compliance. 

        17.5    Severability.    The provisions of this Agreement shall be deemed severable, and the invalidity or
unenforceability of any provision shall not affect the validity and enforceability of the other provisions hereof. 

        17.6    Headings.    The description headings in this Agreement are inserted for convenience only and do not
constitute a part of this Agreement. 

        17.7    Execution in Counterpart.    This Agreement may be executed in any number of counterparts, each of which shall
be deemed an original. 

        17.8    Entire Agreement.    This writing constitutes the entire agreement of the parties and there are no promises,
understandings or agreements of any kind pertaining to this Agreement other than those written in this Agreement. This Agreement supercedes all previous Agreements in this matter. 

(signature
page follows) 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

11

 

        IN WITNESS WHEREOF, the parties thereto have executed this Agreement in duplicate originals by their duly authorized officers or
representatives. 

	For LICENSOR:	 	For LICENSEE:
	
GEORGETOWN UNIVERSITY	
 	

PROLX PHARMACEUTICALS
	

By:	
 	

/s/ William J. Hartman
 William J. Hartman

Director, Research & Technology	
 	

/s/ Lynn Kirkpatrick
 Dr. Lynn Kirkpatrick
	

 	
 	

    6/29/01
 Date	
 	

    6/26/01
 Date
	

By:	
 	

/s/ Pim Thukrall        07/2/01
 Pim Thukrall

CFO

Georgetown University Medical Center	
 	

 
	

 	
 	

/s/ Pete J. Lynn        7/2/01
 Witness	
 	

/s/ Kristen Geary
 Witness

	
ARIZONA BOARD OF REGENTS

On behalf of

THE UNIVERSITY OF ARIZONA	
 	

 

	

By:	
 	

/s/ Richard C. Powell
 Signature	
 	

 
	

 	
 	

Richard C. Powell
 Print Name	
 	

 
	

 	
 	

    7/9/01
 Date	
 	

 
	

 	
 	

/s/ Mary W. Trimmell
 Witness	
 	

 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

12

 
 
 

APPENDIX A    
    

Licensed Applications  

	1.
	[+]

	2.
	[+]

	3.
	[+]

	4.
	[+]

Licensed Patent  

	1.
	[+] 

[+]
DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED FOR CONFIDENTIALITY PURPOSES 

13

QuickLinks

EXCLUSIVE LICENSE AGREEMENT AMONG GEORGETOWN UNIVERSITY AND THE UNIVERSITY OF ARIZONA AND PROLX PHARMACEUTICALS CORPORATION

APPENDIX AQuickLinks
 -- Click here to rapidly navigate through this document

Exhibit 10.13  

 
 

CONSENT AND ACKNOWLEDGEMENT    
    

AMONG:

BIOMIRA INC.
  —and—
 BIOMIRA INTERNATIONAL INC.
  —and—
 BIOMIRA EUROPE
B.V.

(collectively, as applicable, "Biomira")
  —and—
 IMPERIAL CANCER RESEARCH TECHNOLOGY LIMITED
  —and—
 MERCK KGaA

WHEREAS: 

A.    Biomira
and Imperial Cancer Research Technology Limited, a company registered in England and Wales ("ICRT"), are parties to an amended and restated license agreement dated effective
November 14, 2000 (the "License Agreement") pursuant to which ICRT granted, subject to the terms of
the License Agreement, an exclusive, worldwide license under the Licensed Patents to develop, make, have made, possess, utilize, sell, have sold, and otherwise exploit the ICRT Licensed Products and
ICRT/DF Licensed Products in the Territory in the Field (the "ICRT Licensed Technology"), as each of the capitalized terms are defined in the License Agreement; 

B.    Biomira
and Merck KGaA, a German corporation (the "Sublicensee"), have formed a collaboration (the "Collaboration") concerning, among other things, the development, promotion,
manufacture and supply of Biomira's BLP-25 product; 

C.    The
Sublicensee and Biomira wish to confirm the consent (as required pursuant to the terms of the License Agreement) of ICRT with respect to the sublicense by Biomira to the
Sublicensee of the ICRT Licensed Technology, the right of the Sublicensee to sublicense the ICRT Licensed Technology to affiliates of the Sublicensee, and the right of the Sublicensee (or a designated
affiliate of the Sublicensee), under certain circumstances, to cure defaults under the License Agreement on behalf of Biomira in order to maintain the License Agreement. 

        THEREFORE,
in consideration of the premises and other good and valuable consideration (the receipt and sufficiency of which is hereby acknowledged by Biomira, ICRT and the Sublicensee),
the parties hereby covenant and agree as follows: 

 
 

ARTICLE 1
  Definitions    
    

	1.
	In
this Agreement, including the Preamble and Schedules hereto (this "Agreement"), unless otherwise defined, capitalized terms shall have the meanings set forth for those terms in the
License Agreement. 

 
 
 

ARTICLE 2
  Provide Notices    
    

	2.
	ICRT
hereby agrees to provide prompt written notice (a "Default Notice") to the Sublicensee of:

	(a)
	any
notice provided by ICRT to Biomira pursuant to Section 4.6 of the License Agreement; and

	(b)
	any
default notice provided by ICRT to Biomira under the License Agreement under section 9.2. 

All
such Default Notices shall be provided concurrently with any notices given by ICRT pursuant to the License Agreement. 

 
 

ARTICLE 3
  Default    
    

	3.
	Upon
the Sublicensee's receipt of a Default Notice, the following provisions shall apply:

	(a)
	Biomira
shall continue to have the time periods (each such period, the "Time Period") described in section 4.6 and 9.2 of the License Agreement to cure the breach or default
(the "Default") which gave rise to the Default Notice; and

	(b)
	if
Biomira does not cure the Default within the applicable Time Period, prior to the exercise of any of ICRT's rights or remedies under the License Agreement, ICRT agrees to provide
the Sublicensee with further written notice (the "Further Default Notice") specifying the nature of the Default and confirming that Biomira has failed to remedy the Default within the applicable Time
Period, if any, and the Sublicensee shall then have an additional forty-five (45) day period after the delivery of the Further Default Notice to cure the Default. The parties hereto
acknowledge that the Sublicensee has no obligation to cure a Default. If the Sublicensee cures such Default on behalf of Biomira, the Default shall for purposes of the License Agreement be deemed to
have been cured during the applicable grace period and the License Agreement shall continue in full force and effect. 

 
 

ARTICLE 4
  Consent to Sublicense    
    

	4.
	ICRT
hereby consents to Biomira's sublicense of the ICRT Licensed Technology to the Sublicensee on the terms of the Collaboration as further described in the collaboration agreement
dated May 3, 2001 between Biomira and the Sublicensee (the "Collaboration Agreement"), the applicable portions of which are summarized in Schedule "C" hereto and/or attached as Schedule "A"
hereto, and in the supply agreement dated May 3, 2001 between Biomira and the Sublicensee, the applicable portions of which are summarized in Schedule "C" hereto and/or attached as Schedule "B"
hereto (collectively, the "Sublicense"). A certificate of an officer of Biomira is attached as Schedule "D" hereto certifying that the summary and extracts attached as Schedules "A", "B" and "C" are,
in all material respects, true and complete summaries and/or extracts of all portions of the Sublicense pertaining to the sublicense under the License Agreement. ICRT also hereby consents to the
further sublicense of the ICRT Licensed Technology by the Sublicensee to affiliates of the Sublicensee on similar terms as the Collaboration. Such consents of ICRT to sublicense are not and shall not
be deemed to be approval of or consent to the terms of the Sublicense for the purposes of clause 3.3(d) of the License Agreement. ICRT hereby acknowledges that the Collaboration Agreement
incorporates by reference any provision specifically required by the License Agreement to be included in such Sublicense. ICRT hereby agrees to such incorporation by reference. 

2

 
 
 

ARTICLE 5
  Consent to Assignment    
    

	5.
	ICRT
covenants and agrees with the Sublicensee and Biomira that if Biomira and the Sublicensee agree in writing to assign Biomira's interest in the License Agreement to the Sublicensee
(or an affiliate of the Sublicensee), and if Biomira and the Sublicensee provide written notice to ICRT of such assignment, ICRT will consent to the absolute assignment and transfer of Biomira's
interest in the License Agreement to the Sublicensee (or the designated affiliate of the Sublicensee) provided that:

	(a)
	the
Sublicensee (or the designated affiliate of the Sublicensee) agrees to comply with the covenants and agreements set out in the License Agreement from and after the date of such
assignment and transfer; and

	(b)
	the
Sublicensee (or the designated affiliate of the Sublicensee) is at such time compliant with the License Agreement, to the extent that the provisions of the License Agreement can
be applied to the activities of the Sublicensee (or the designated affiliate of the Sublicensee). 

 
 

ARTICLE 6
  Notice    
    

	6.
	Any
notices (including, without limitation, a Default Notice) to be delivered under this agreement shall be delivered to the Sublicensee by courier or telecopy at the address or
telecopy number described below or such other address or telecopy number as may be designated from time to time by the Sublicensee: 

Merck
KGaA

Frankfurter Strasse 250

D-64293 Darmstadt

Germany

Attention: Legal Department

Facsimile: 49-6151-72-2373 

 
 

ARTICLE 7
  Governing Law    
    

	7.
	This
Agreement shall be governed by the, and constituted in, accordance with the laws of the domicile of the defendant in any given proceeding and the parties hereby submit to the
exclusive jurisdiction of the Courts of such domicile for such proceeding. 

 
 

ARTICLE 8
  Enurement    
    

	8.
	This
Agreement shall enure to the benefit of and be binding upon the parties hereto and their successors and assigns. 

 
 

ARTICLE 9
  Counterparts    
    

	9.
	This
Agreement may be executed in any number of counterparts, which when taken together, shall form one agreement. 

3

 
 
 

ARTICLE 10
  Execution by Facsimile    
    

	10.
	A
facsimile copy of an executed copy of this Agreement shall have the same force and effect as an originally executed copy of this Agreement. 

        This
Agreement has been executed by the parties on the dates set forth opposite their names. 

	 	 	BIOMIRA INC.
	

Executed on Nov. 30, 2001	
 	

Per:	
 	

/s/ Edward Taylor

	

 	
 	
BIOMIRA INTERNATIONAL INC.
	

Executed on Nov. 30, 2001	
 	

Per:	
 	

/s/ W. Vickery Stoughton

	

 	
 	
BIOMIRA EUROPE B.V.
	

Executed on Nov. 30, 2001	
 	

Per:	
 	

/s/ W. Vickery Stoughton

	

 	
 	
IMPERIAL CANCER RESEARCH TECHNOLOGY LIMITED
	

Executed on                          2001	
 	

Per:	
 	

    

	

 	
 	

Per:	
 	

    

	

 	
 	
MERCK KGaA
	

Executed on February 5, 2002	
 	

Per:	
 	

/s/

	

 	
 	

Per:	
 	

/s/

4

QuickLinks

CONSENT AND ACKNOWLEDGEMENT

ARTICLE 1 Definitions

ARTICLE 2 Provide Notices

ARTICLE 3 Default

ARTICLE 4 Consent to Sublicense

ARTICLE 5 Consent to Assignment

ARTICLE 6 Notice

ARTICLE 7 Governing Law

ARTICLE 8 Enurement

ARTICLE 9 Counterparts

ARTICLE 10 Execution by Facsimile

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}]]